Kabra Drugs Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Revenue	573.34	-	-	-	-	-
Cost of Revenue	505.98	-	-	-	-	-
Gross Profit	67.36	-	-	-	-	-
Selling, General & Admin	14.34	7.55	4.55	2.64	1.2	0.7
Other Operating Expenses	15.87	9.63	2.82	0.81	0.55	0.78
Operating Expenses	30.54	17.25	7.36	3.44	1.84	1.79
Operating Income	36.82	-17.25	-7.36	-3.44	-1.84	-1.79
Interest Expense	-0.03	-	-	-	-	-
Interest & Investment Income	-	-	-	0.06	-	-
Other Non Operating Income (Expenses)	10.19	6.4	-	-	-	-
EBT Excluding Unusual Items	46.99	-10.85	-7.36	-3.38	-1.84	-1.79
Gain (Loss) on Sale of Investments	-	-	-	-	-0.01	-0.01
Pretax Income	46.99	-10.85	-7.36	-3.38	-1.85	-1.8
Income Tax Expense	4.02	0.01	-	-	-	-
Net Income	42.96	-10.86	-7.36	-3.38	-1.85	-1.8
Net Income to Common	42.96	-10.86	-7.36	-3.38	-1.85	-1.8
Shares Outstanding (Basic)	21	11	4	4	4	4
Shares Outstanding (Diluted)	21	11	4	4	4	4
Shares Change (YoY)	144.81%	149.01%	-	-	-	-
EPS (Basic)	2.03	-0.99	-1.68	-0.77	-0.42	-0.41
EPS (Diluted)	2.03	-0.99	-1.68	-0.77	-0.42	-0.41
Free Cash Flow	-	-47.58	-2.09	-3.54	-1.34	-2.49
Free Cash Flow Per Share	-	-4.35	-0.47	-0.81	-0.30	-0.57
Gross Margin	11.75%	-	-	-	-	-
Operating Margin	6.42%	-	-	-	-	-
Profit Margin	7.49%	-	-	-	-	-
EBITDA	36.93	-17.18	-	-3.34	-1.74	-1.48
EBITDA Margin	6.44%	-	-	-	-	-
D&A For EBITDA	0.11	0.07	-	0.1	0.1	0.31
EBIT	36.82	-17.25	-7.36	-3.44	-1.84	-1.79
EBIT Margin	6.42%	-	-	-	-	-
Effective Tax Rate	8.56%	-	-	-	-	-
Revenue as Reported	583.53	6.4	-	0.06	-	-
Advertising Expenses	-	0.17	0.19	0.09	0.07	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.